Se2Mo10V3, a heteropoly compound containing selenium, inhibits tumor growth
Metrics: PDF 1025 views | HTML 1480 views | ?
Hong-Ning Zhang1, Wei-Li Feng2, Chun-Na An3 and Wen-Guang Li4
1Department of Pharmacology, School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China
2Department of Pharmacology, School of Basic Medical Sciences, Qinghai University, Xining 810001, China
3Department of Pharmacology, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan 063009, China
4Department of Pharmacology, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China
Chun-Na An, email: [email protected]
Wen-Guang Li, email: [email protected]
Keywords: heteropoly compound containing selenium, Se2Mo10V3, anti-tumor, apoptosis, NF-κB/IκBα
Received: March 21, 2017 Accepted: May 30, 2017 Published: July 01, 2017
Selenium compounds have strong anti-tumor effects and are well-tolerated. We examined the anti-tumor effects of (NH4)2H15Se2VIMo10V3O52·2H2O (Se2Mo10V3), a heteropoly compound containing selenium. Se2Mo10V3 inhibited proliferation in K562 cells with a half-maximal inhibitory concentration of 78.72±2.82 mg/L after 48 h and 24.94±0.88 mg/L after 72 h. Typical apoptotic morphologies were also observed in K562 cells treated with Se2Mo10V3, as were increased intracellular levels of Ca2+, Mg2+, H+, and reactive oxygen species, and decreased mitochondrial membrane potential. In addition, Se2Mo10V3 treatment triggered cytochrome C release and inhibited IκBα degradation and NF-κB translocation. In vivo experiments revealed that 5 or 10 mg/kg Se2Mo10V3 inhibited the growth of sarcoma 180 and hepatoma 22 xenograft tumors. These results indicate that Se2Mo10V3 inhibits tumor growth both in vitro and in vivo and induces apoptosis in K562 cells, possibly by inhibiting the NF-κB/IκBα pathway.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.